Results 141 to 150 of about 213,618 (247)

Harnessing Transformation of Metal-Ligand Coordination in Dinuclear Ni(II)-Schiff Base Coordination Polymer for Promoting Electrochemical Oxygen Evolution. [PDF]

Adv Sci (Weinh)
Juang RH, Li HJ, Chang YC, Chang CW, Fan RY, Kong KV, Chen JL, Hsu CS, Lin PH, Kuo CH.   +9 more
europepmc   +1 more source

ABL kinase‐dependent phosphorylation of SH proteins promotes their direct interaction with CRK family SH2 domains

FEBS Letters, EarlyView.
CT10 regulator of kinase (CRK) and CRK‐Like (CRKL) are signaling adaptors driving cell adhesion, motility, differentiation, and proliferation. SH2‐domain containing (SH) proteins are enriched in YXXP motifs which when phosphorylated create preferred binding sites for CRK family SH2 domains.
Phoebe M. Cousens, Brendan W. Chandler, Anna M. Schmoker, Jaye L. Weinert, Charlotte A. Kearns, Warren T. Yacawych, Amila Šemić, Alicia M. Ebert, Bryan A. Ballif   +8 more
wiley   +1 more source

Ni(II) Chiral Square-Complex-Mediated Mannich Alkynylation for the Synthesis of Enantiomerically Enriched Unnatural α‑Amino Acids with Collagenase Inhibitory Activity. [PDF]

ACS Omega
Grigoryan A, Hayriyan L, Gevorgyan H, Sargsyan A, Langer P, Saghyan A, Mkrtchyan A.   +6 more
europepmc   +1 more source

Mixed‐class J‐domain protein scaffolds promote expanded aggregate handling and multivalent Hsp70 engagement during functional disaggregase assembly

FEBS Letters, EarlyView.
Protein aggregates threaten proteostasis and cell health. In human cells, Hsp70–J‐domain protein‐based disaggregases remove aggregates, but how they assemble remains unclear. Our biochemical findings show that DNAJA2‐ and DNAJB1‐containing disaggregase scaffolds enhance luciferase aggregate targeting, and that Hsp70 recruitment by both J‐domain ...
Anna Szlachcic, Nadinath B. Nillegoda
wiley   +1 more source

Micro-array based on parafilm towards the opto-analysis of Cu(ii), Cr(vi), and Ni(ii) ions in fish samples by specific indicators: a state-of-the-art approach. [PDF]

RSC Adv
Bahavarnia F, Kordasht HK, Hasanzadeh M, Shadjou N.   +3 more
europepmc   +1 more source

Reconstructing enzyme evolution by protein engineering

FEBS Letters, EarlyView.
Natural enzyme evolution can be retraced by protein engineering methods such as directed evolution, rational design, and ancestral sequence reconstruction. These approaches reveal how enzymes emerged from ligand‐binding scaffolds, developed varying substrate preferences, formed oligomeric complexes, adapted to environmental changes, and evolved novel ...
Lukas Drexler, Markus R. Busch, Reinhard Sterner   +2 more
wiley   +1 more source

Zeolite Heulandite Modified with N,N'-bis(3-Triethoxysilylpropyl)thiourea-Adsorption of Ni(II) and Cu(II) Ions: A Quantum Chemical Insight into the Mechanism. [PDF]

Molecules
Filatova EG, Nalibayeva AM, Lebedeva OV, Beznosyuk SA, Ryabykh AV, Oborina EN, Abdikalykov YN, Turmukhanova MZ, Rozentsveig IB, Adamovich SN.   +9 more
europepmc   +1 more source

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

Molecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce, Simone Bini, Marialuisa Sponziello, Giorgio Grani, Giulia Fiscon, Paola Paci, Lorenzo Farina, Rosa Falcone, Valentina Maggisano, Sebastiano Filetti, Cosimo Durante, Antonella Verrienti   +11 more
wiley   +1 more source

Efficiency of <i>Spirulina</i> sp. in the Treatment of Model Wastewater Containing Ni(II) and Pb(II). [PDF]

Materials (Basel)
Sočo E, Domoń A, Azizi M, Pająk D, Cieniek B, Michel MM, Papciak D.   +6 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source